From the miRoncol archive: This historical update may contain promotional language or research findings that do not describe the current service. Retrospective research results do not establish prospective screening performance, and references to scientific prizes do not imply evaluation or endorsement of miRoncol or miCheckup. Do not rely on this archive for healthcare decisions; use the current product information and discuss screening decisions with a healthcare professional.
Editorial update — September 11, 2026: An earlier version described a planned launch using “world's first,” “category-defining” and “groundbreaking” language. Those promotional claims have been removed.
miRoncol Health CEO Victoria Xu presented the company's microRNA research and Canadian development plans during Elevate Festival's opening night in October 2025.
The presentation discussed miRoncol's work on blood-based models designed to identify patterns associated with multiple cancer types. Research findings and development plans should not be interpreted as established commercial screening performance, regulatory approval or a guarantee of an individual health outcome.